Tyverb in combination with AI: safety

Tyverb has a well-established safety profile1,2

Safety in the pivotal study EGF30008

The safety of Tyverb in combination with an aromatase inhibitor (AI) was evaluated in the pivotal phase III EGF30008 study. In this study, all patients of the combination group received letrozole.1

Tyverb in combination with an AI represents an effective treatment option in HER2+ hormone receptor-positive (HR+) metastatic breast cancer that could delay the need for chemotherapy in appropriate patients.1

Adverse events in the safety population of the pivotal EGF30008 study1

Adapted from Johnston S, Pippen J Jr, Pivot X, et al. J Clin Oncol. 2009;27:5538–5546.

Adverse events in the HER2+ population of the pivotal EGF30008 study

Grade1/2 diarrhoea and rash were the most frequent adverse events in the HER2+ HR+ population.3

9% of patients experienced grade 3 diarrhoea.2 In the majority of cases (93%), diarrhoea resolved with no action. Where action was required, diarrhoea was effectively managed by dose reduction (2%) or temporary interruption (4%).3

Further information on the EGF30008 study can be found in the clinical evidence section.

Tyverb in combination with an AI: dosing

References: 1. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27:5538–5546. 2. Tyverb® (lapatinib) Summary of Product Characteristics. Camberley, UK: Novartis Europharm Limited; 11 August 2015. 3. Schwarzberg L, Franco S, Florance A, et al. Lapatinib plus letrozole as first-line therapy for HER2+ hormone receptor-positive metastatic breast cancer. Oncologist. 2010;15:122–129.